Yan Leyfman, Co-founder and executive director of MedNews Week, shared an article by Adetola A. Kassim, et al. on LinkedIn:
“Promising Results for Sickle Cell Transplant!
A new study shows HLA-haploidentical bone marrow transplantation (BMT) with post-transplant cyclophosphamide may be a curative option for adults with sickle cell disease.
- 88% event-free survival at 2 years.
- 95% overall survival.
- Low rates of severe GVHD (4.8%).
- Challenges remain: infections & graft failure.
These findings support BMT as a viable therapy, but risks must be carefully managed.”
Haploidentical Bone Marrow Transplantation for Sickle Cell Disease.
Authors: Adetola A. Kassim, et al.
